Nurix Therapeutics, Inc. (NRIX)
15.95
-9.87
(-38.23%)
USD |
NASDAQ |
Nov 04, 16:00
15.99
+0.04
(+0.25%)
Pre-Market: 08:54
Nurix Therapeutics Enterprise Value : 758.82M for Nov. 4, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2026 | 758.82M |
| November 03, 2026 | 1.837B |
| November 02, 2026 | 1.824B |
| October 30, 2026 | 1.944B |
| October 29, 2026 | 1.979B |
| October 28, 2026 | 1.994B |
| October 27, 2026 | 1.933B |
| October 26, 2026 | 1.807B |
| October 23, 2026 | 1.784B |
| October 22, 2026 | 1.803B |
| October 21, 2026 | 1.858B |
| October 20, 2026 | 1.867B |
| October 19, 2026 | 1.739B |
| October 16, 2026 | 1.684B |
| October 15, 2026 | 1.742B |
| October 14, 2026 | 1.602B |
| October 13, 2026 | 1.434B |
| October 12, 2026 | 1.437B |
| October 09, 2026 | 1.458B |
| October 08, 2026 | 1.442B |
| October 07, 2026 | 1.499B |
| October 06, 2026 | 1.485B |
| October 05, 2026 | 1.516B |
| October 02, 2026 | 1.528B |
| October 01, 2026 | 1.566B |
| Date | Value |
|---|---|
| September 30, 2026 | 1.606B |
| September 29, 2026 | 1.602B |
| September 28, 2026 | 1.602B |
| September 25, 2026 | 1.530B |
| September 24, 2026 | 1.600B |
| September 23, 2026 | 1.625B |
| September 22, 2026 | 1.820B |
| September 21, 2026 | 1.792B |
| September 18, 2026 | 1.795B |
| September 17, 2026 | 1.802B |
| September 16, 2026 | 1.763B |
| September 15, 2026 | 1.729B |
| September 14, 2026 | 1.804B |
| September 11, 2026 | 1.758B |
| September 10, 2026 | 1.836B |
| September 09, 2026 | 1.885B |
| September 08, 2026 | 1.870B |
| September 04, 2026 | 1.872B |
| September 03, 2026 | 1.782B |
| September 02, 2026 | 1.837B |
| September 01, 2026 | 1.861B |
| August 31, 2026 | 1.832B |
| August 28, 2026 | 2.333B |
| August 27, 2026 | 2.402B |
| August 26, 2026 | 2.384B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 234.72B |
| ACADIA Pharmaceuticals, Inc. | 2.813B |
| Alnylam Pharmaceuticals, Inc. | 20.97B |
| Anika Therapeutics, Inc. | 259.85M |
| Savara, Inc. | 814.53M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 549.81M |
| Revenue (Quarterly) | 673.06M |
| Total Expenses (Quarterly) | 123.26M |
| EPS Diluted (Quarterly) | 4.734 |
| Gross Profit Margin (Quarterly) | 99.46% |
| Profit Margin (Quarterly) | 81.69% |
| Earnings Yield | 14.50% |
| Operating Earnings Yield | 16.80% |
| Normalized Earnings Yield | 14.50 |